Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $132,000.

  • Stoke Therapeutics' Capital Expenditures rose 28.16% to $132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $480,000, marking a year-over-year increase of 23.08%. This contributed to the annual value of $203,000 for FY2024, which is 87.44% down from last year.
  • As of Q3 2025, Stoke Therapeutics' Capital Expenditures stood at $132,000, which was down 14.29% from $154,000 recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Capital Expenditures peaked at $2.0 million during Q3 2022, and registered a low of $12,000 during Q1 2024.
  • In the last 3 years, Stoke Therapeutics' Capital Expenditures had a median value of $152,000 in 2025 and averaged $205,182.
  • Per our database at Business Quant, Stoke Therapeutics' Capital Expenditures plummeted by 97.80% in 2024 and then skyrocketed by 1,166.67% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Capital Expenditures (Quarterly) stood at $409,000 in 2022, then plummeted by 44.01% to $229,000 in 2023, then crashed by 81.66% to $42,000 in 2024, then increased by 28.16% to $132,000 in 2025.
  • Its Capital Expenditures was $132,000 in Q3 2025, compared to $154,000 in Q2 2025 and $152,000 in Q1 2025.